Glofitamab-Gxbm 1 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg/mL

Reference Brands: Columvi (USA/EU)

Category: Oncology Cancer Care

Glofitamab-gxbm is a bispecific monoclonal antibody that targets both CD20 (on B cells) and CD3 (on T cells). It helps the patient’s immune system attack and destroy malignant B cells. It is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Product Description:

Glofitamab is a bispecific antibody with an unusual configuration: it carries two binding sites for CD20 on the malignant B cell and one for CD3 on the T cell. The two-to-one geometry gives it a firmer grip on the tumour cell than conventional bispecifics, which matters in lymphomas where CD20 density has already been reduced by prior rituximab exposure.

It is used for relapsed or refractory diffuse large B-cell lymphoma after two or more prior lines, given intravenously. Two features define its practical use. First, treatment is given for a fixed duration — around twelve cycles — rather than continuing until progression, so patients have a defined endpoint and a period off therapy. Second, a dose of obinutuzumab is given a week beforehand to strip circulating B cells and blunt cytokine release syndrome, which is otherwise a serious risk, as is immune effector cell-associated neurotoxicity. Step-up dosing and hospital observation are required.

Sourcing notes. Originator biologic under patent. Because a separate antibody is mandatory as pretreatment, quotations should cover both products rather than this one alone. Cold chain at 2–8 degrees, do not freeze or shake. The receiving centre must be equipped for cytokine release syndrome management.